Johnson & Johnson (NYSE:JNJ) Holdings Decreased by Keystone Financial Planning Inc.

Keystone Financial Planning Inc. trimmed its position in Johnson & Johnson (NYSE:JNJ) by 3.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,145 shares of the company’s stock after selling 415 shares during the quarter. Keystone Financial Planning Inc.’s holdings in Johnson & Johnson were worth $1,605,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Pathway Financial Advisors LLC increased its holdings in shares of Johnson & Johnson by 4.3% in the 4th quarter. Pathway Financial Advisors LLC now owns 5,438 shares of the company’s stock valued at $852,000 after acquiring an additional 226 shares during the last quarter. Daiwa Securities Group Inc. boosted its position in Johnson & Johnson by 5.5% during the 4th quarter. Daiwa Securities Group Inc. now owns 297,850 shares of the company’s stock valued at $46,685,000 after purchasing an additional 15,490 shares during the period. OneAscent Financial Services LLC boosted its position in Johnson & Johnson by 82.8% during the 4th quarter. OneAscent Financial Services LLC now owns 9,838 shares of the company’s stock valued at $1,542,000 after purchasing an additional 4,457 shares during the period. Vestmark Advisory Solutions Inc. boosted its position in Johnson & Johnson by 12.7% during the 4th quarter. Vestmark Advisory Solutions Inc. now owns 19,587 shares of the company’s stock valued at $3,070,000 after purchasing an additional 2,201 shares during the period. Finally, TrueMark Investments LLC acquired a new position in Johnson & Johnson during the 4th quarter valued at approximately $1,458,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Up 1.5 %

Johnson & Johnson stock traded up $2.12 during mid-day trading on Thursday, hitting $147.77. The company’s stock had a trading volume of 8,749,383 shares, compared to its average volume of 7,371,235. The firm’s 50 day moving average is $148.02 and its 200 day moving average is $154.45. The company has a market cap of $355.63 billion, a PE ratio of 9.21, a price-to-earnings-growth ratio of 2.42 and a beta of 0.53. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $175.97.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The company had revenue of $21.38 billion during the quarter, compared to the consensus estimate of $21.39 billion. During the same period last year, the business earned $2.68 EPS. The business’s quarterly revenue was up 2.3% on a year-over-year basis. On average, analysts anticipate that Johnson & Johnson will post 10.63 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were issued a dividend of $1.24 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date was Monday, May 20th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.36%. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Analysts Set New Price Targets

JNJ has been the subject of a number of analyst reports. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Thursday. StockNews.com lowered Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Monday, June 10th. Morgan Stanley reduced their price objective on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 17th. HSBC upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price target for the stock from $169.00 to $170.00 in a research report on Thursday, April 18th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $175.00 price target on shares of Johnson & Johnson in a research note on Monday. Eight research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $174.07.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.